Clenil 50 mcg

Quick links

Choose a section

Quick links to important sections

Advertisements

Clenil 50 mcg

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Clenil 50 mcg

Quick Facts

Property Description
Active ingredient Beclomethasone Dipropionate (BDP)
Form Pressurised Inhalation Solution (Metered-Dose Inhaler)
Pharmacological class Inhaled Glucocorticoid (Corticosteroid)
General purpose Prophylactic treatment (long-term prevention)
Origin Synthetic

What Type of Medicine is Clenil 50 mcg?

Clenil 50 mcg is a prescription-only medicine whose active ingredient is Beclomethasone Dipropionate (BDP), which classifies it as an inhaled glucocorticoid within the broader corticosteroid drug class. The compound is a synthetic diester, chemically optimized for effective, localized delivery to the airways. This medicine is designed as a single-active-ingredient product intended for long-term respiratory management.


Form, Composition, and General Purpose

This product is supplied as a pressurised inhalation solution dispensed via a Metered-Dose Inhaler (MDI), intended for direct oral inhalation. The 50 mcg value precisely quantifies the Beclomethasone Dipropionate delivered with each actuation. The solution is suspended in an inert propellant, such as Hydrofluoroalkane (HFA-134a), which is essential for ensuring efficient atomization and delivery of the dose into the lungs. The general purpose of this specific inhaled form is to act as a prophylactic treatment by continuously applying anti-inflammatory action directly to the respiratory tract, thereby helping to stabilize the airways for maintenance therapy.

Regulatory References

  1. Beclomethasone Oral Inhalation Drug Information
Advertisements

What side effects are possible with Clenil 50 mcg?

Possible side effects and safety information

The official safety profile for Clenil 50 mcg (Beclomethasone Dipropionate) classifies possible adverse reactions by frequency and physiological system, based on governmental regulatory documents.


Adverse Reaction Frequency Classification

Classification Examples of Reactions
Very Common Oral candidiasis of the mouth and throat.
Common Hoarseness, throat irritation.
Uncommon Rash, urticaria, pruritus, erythema.
Very Rare Anaphylactic reactions, Cushing's features, adrenal suppression, growth retardation, decreased bone mineral density, cataract, glaucoma.
Not Known Blurred vision, psychomotor hyperactivity, anxiety, depression, aggression (predominantly in children).

These effects are grouped into System-Organ Classes (SOCs), including Infections and Infestations, Endocrine Disorders, Psychiatric Disorders, Eye Disorders, and Respiratory, Thoracic and Mediastinal Disorders.


Serious Adverse Reactions and Safety Patterns

Official labeling documents specific safety considerations:

  • Serious Adverse Reactions: These include paradoxical bronchospasm, defined as an immediate and severe increase in wheezing that occurs shortly after administration, and acute adrenal crisis resulting from adrenal suppression.
  • Dose and Duration Patterns: Systemic effects, such as adrenal suppression and decreased bone mineral density, are documented as more likely to occur with high doses prescribed for prolonged periods.
  • Population Notes: There is a documented risk of growth retardation in children, and the product's safety is not fully established during human pregnancy.
  • Safety Restrictions: This medicine is not to be used for the primary treatment of status asthmaticus or acute bronchospasm. Caution is officially advised in patients with active or quiescent pulmonary tuberculosis or untreated systemic infections.

The regulatory safety structure emphasizes a distinction between common, localized effects and the low-frequency potential for systemic corticosteroid-related risks, which require specific monitoring attention.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Clenil 50 mcg (Beclomethasone Dipropionate) focuses on the consequences of chronic, prolonged use of doses exceeding those recommended, rather than acute single-event toxicity.


Documented Overdose Manifestations

Prolonged high exposure may lead to systemic effects, including signs of Hypercorticism and Cushingoid features. The primary physiological finding is Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which is the basis for most severe outcomes.


Required Emergency Actions

HPA-axis suppression creates a risk of a life-threatening acute adrenal crisis during times of intense physiological stress, such as major surgery, severe infection, or trauma. Urgent medical assessment is mandatory if a patient on high-dose therapy experiences a sudden and progressive deterioration in their symptoms. During stress or elective surgery, additional systemic corticosteroid cover may be required.


Management and Monitoring

  • Antidote: No specific antidote is known for this active substance.
  • Treatment: Management involves symptomatic and supportive measures. Regulatory guidance requires the gradual withdrawal of the corticosteroid if overexposure is confirmed, and adrenocortical function monitoring for at-risk patients.
  • Pediatric Note: A population-specific risk is the potential for growth retardation in children exposed to prolonged, high doses.
Advertisements

Therapeutic Uses of Clenil 50 mcg

What Clenil 50 mcg Treats: Main Uses and Benefits

Clenil 50 mcg, containing the corticosteroid beclometasone dipropionate, is applied in addressing conditions characterized by periods of heightened symptoms, such as the maintenance treatment of asthma. This medication is commonly used across conditions presenting with acute episodes, providing supportive care.

This medication is indicated for the maintenance treatment of asthma in adults and children. This makes it relevant in clinical settings that involve acute or unstable symptom patterns, and is considered relevant in contexts involving heightened systemic burden.

It helps manage symptoms related to physical discomfort and symptoms that interfere with daily functioning by contributing to improved comfort during periods of heightened symptoms. It may assist with maintaining functional stability.

Quick Fact: Supports Management of Symptom Clusters that May Become Intense

It provides support that helps ease the overall symptom burden. It is applied across domains where additional symptomatic support is needed.

Regulatory References

  1. EMA therapeutic agreement on Clenil
Advertisements

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label): The medicine is approved for the prophylactic management of asthma in adults and the elderly. Use is also approved for children and adolescents, with the lower age limit for MDI use established as 4 years of age and older. Patients with hepatic or renal impairment are included in the standard eligible population, as no dosage adjustment is officially required.


Populations for whom use is contraindicated: Clenil 50 mcg is contraindicated for the primary treatment of status asthmaticus or other acute episodes of asthma where intensive rescue measures are required. It must also not be used by patients with a known hypersensitivity to beclometasone dipropionate or any of the product’s excipients.


Eligibility-related restrictions: Conditional caution is required for patients with active or quiescent tuberculosis or other untreated systemic infections (e.g., fungal or viral). Particular care is necessary when transferring patients from systemic (oral) corticosteroids due to the risk of impaired adrenal function. The growth rate of pediatric patients should be monitored closely. For women who are pregnant or breastfeeding, use should only be considered if the expected benefit to the mother is determined to outweigh any possible risk.

Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Clenil 50 mcg (Beclomethasone dipropionate) documents clinically relevant interactions primarily related to the metabolic pathway of the drug’s active component.

Documented Interaction Categories

Interacting Product Category Key Restrictions and Requirements
Potent CYP3A4 Inhibitors Co-administration is expected to increase the systemic exposure of the active metabolite.
Alcohol-Interacting Medicines Caution is advised due to the trace amount of ethanol (alcohol) present in the formulation.

Interacting Medicines Explicitly Listed

The most commonly listed specific medicines that can cause this interaction are those used for treating HIV, specifically Ritonavir and Cobicistat. These medicines are classified as potent inhibitors of the Cytochrome P450 3A4 (CYP3A4) enzyme system, which is responsible for the metabolism of the active metabolite of the drug. The inhibition of this enzyme can lead to increased systemic levels of the corticosteroid component.

Practical Management Constraints

Regulatory documents mandate that healthcare providers must carefully monitor patients who are concurrently taking this product with potent CYP3A4 inhibitors. This requirement is in place to manage the risk of potential systemic corticosteroid effects resulting from increased exposure. Additionally, the small ethanol content in the product requires caution when co-administered with medicines like Disulfiram or Metronidazole.

Advertisements

Mechanism of Action

How Clenil 50 mcg Works

Clenil's active component, Beclomethasone dipropionate, is a prodrug that is rapidly converted to its primary active metabolite, Beclomethasone 17-monopropionate (17-BMP), upon reaching the airways. This metabolite functions as an agonist by binding to the intracellular Glucocorticoid Receptor (GR) found in target cells (e.g., epithelial and inflammatory cells).

The activated 17-BMP–GR complex translocates to the cell nucleus to modulate gene transcription via Transrepression. This process involves the complex suppressing the activity of pro-inflammatory transcription factors, such as NF-kappaB, resulting in the downregulation of gene expression for mediators like cytokines, chemokines, and leukotrienes. This molecular cascade leads to a reduction in the number and activity of inflammatory cells (e.g., eosinophils) within the airway mucosa.

The overall physiological consequence of this mechanism is the stabilization of local vascular permeability and the progressive reduction of mucosal oedema (swelling) within the bronchial walls. This decreased tissue inflammation and reduced mediator release lowers the overall airway hyper-responsiveness of the respiratory passages.

Advertisements

Dosage and Administration Information

How to Use Clenil 50 mcg

The administration of Clenil 50 mcg, which contains beclomethasone dipropionate, is strictly by oral inhalation using a Metered-Dose Inhaler (MDI), designed for the continuous, long-term maintenance treatment of respiratory conditions. The drug is not intended for the immediate management of acute breathing distress.

Official Dosing Regimens

Official regulatory guidelines define specific starting and maximum daily doses that are typically divided for administration throughout the day:

Population Typical Starting Dose Maximum Recommended Daily Dose
Adults 200 mcg (4 inhalations) twice daily 800 mcg (16 inhalations)
Children (e.g., ages 5-12) 100 mcg (2 inhalations) twice daily 400 mcg (8 inhalations)

Treatment is initiated at the standard dose and subsequently titrated down to the lowest effective dose required to maintain control. Dosing frequency is usually twice daily (morning and evening) but may be divided into three or four administrations as needed.

Required Administration Protocol

For correct delivery and procedural safety, specific steps must be followed. The inhaler must be primed (actuated into the air, typically two times) if it is new or has been unused for 10 days or longer. After the inhalation of the prescribed dose, the patient is required to rinse their mouth with water without swallowing. This procedural step is essential to manage localized residue. The official labeling also recommends or mandates the use of a spacer device, particularly for children, to improve drug deposition and effectiveness.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Clenil 50 mcg

Evidence for Use in Chronic Asthma Maintenance

The research base for using Beclomethasone Dipropionate (BDP) in the prophylactic management of chronic asthma relies on evidence from numerous studies, primarily consisting of Randomized Controlled Trials (RCTs). Research examined BDP primarily in populations with persistent asthma, including both adults and children aged 5 years and older. Studies explored outcomes related to physical discomfort and systemic or functional imbalance, such as measuring changes in pulmonary function (like FEV1) and documenting the frequency of episodic or acute changes (asthma flare-ups).

Findings describe patterns observed in the studies, particularly concerning the documentation of patient symptoms and the use of short-acting reliever medication. In trials focused on patients requiring continuous oral steroids, research describes the patterns of reduced need for oral steroid reliance in that group. Data also show patterns related to a lower frequency of patient withdrawal from the specific trials, a marker often used to assess exacerbation rates. This evidence contributes to understanding symptom patterns over defined time intervals.


Evidence for Use in Recurrent Wheezing

Research exploring BDP for recurrent wheezing in preschool children (infants up to 5 years old) is less extensive; the evidence is derived from Randomized Clinical Trials (RCTs). In these studies, BDP was evaluated in research scenarios exploring short-term symptom changes. The research examined outcomes describing episodic or acute changes, focusing on the frequency and intensity of wheezing episodes and the subsequent requirement for administering systemic treatment, such as oral corticosteroids.


What Is Still Uncertain About the Research Base

The full body of evidence highlights what is known and what is still uncertain. Research describes limitations related to the depth of data available for certain populations, such as patients with severe asthma, where data for certain groups remain insufficient to fully characterize the relationship between treatment and observed outcomes. Furthermore, studies have explored the effect of substantially increasing the dose above moderate levels on outcomes measured in mild-to-moderate asthma. Therefore, long-term effects for extended exposure in the youngest populations and the precise impact of dose escalation in severe cases are areas where certainty remains limited.

Key Studies & References Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma (NCBI/AHRQ)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Clenil 50 mcg (FAQ)


Q: How long does it typically take to notice a difference after starting Clenil 50 mcg?

According to official product information, the full anti-inflammatory action of the medicine is progressive. The therapeutic effect typically begins to occur after a few days of consistent use. The maximum expected therapeutic action is generally observed after approximately two to three weeks of consistent treatment.


Q: Can Clenil 50 mcg be used by children, and what are the age limits?

Yes, this medicine is officially approved for use in younger populations. Regulatory documents state that it can be used for the prophylactic management of asthma in children aged 4 years and older.


Q: Is Clenil 50 mcg suitable for pregnant or breastfeeding people?

Official documents advise caution regarding use during pregnancy or breastfeeding. They state that the use of this medicine is only to be considered when the expected benefit to the mother is judged to significantly outweigh any possible risk to the baby.


Q: How is Clenil 50 mcg different from other inhalers like Ventolin?

This medicine is an inhaled corticosteroid, which is described as a long-term prophylactic treatment (or 'preventer') that works over time to reduce inflammation. This is functionally different from medicines like Ventolin (salbutamol/albuterol), which are typically classified as short-acting bronchodilators used only for immediate relief of sudden, acute breathing symptoms.


Q: Does Clenil 50 mcg help with allergies or just asthma?

The primary authorized use for this specific inhaled formulation is restricted to the continuous, long-term prophylactic management of asthma. While the active ingredient may be used in other formulations for related conditions, the indications for Clenil 50 mcg are focused on controlling chronic asthma symptoms.


Q: What happens if I stop using Clenil 50 mcg suddenly?

Abruptly stopping treatment may lead to a return or worsening of asthma symptoms. For patients with a history of systemic corticosteroid use, sudden stopping can also risk impaired adrenal function (a condition related to the body's natural hormone production) due to HPA axis suppression.


Q: Can using Clenil 50 mcg affect my mood or sleep?

The class of inhaled corticosteroids has been associated in regulatory documents with potential psychiatric effects. These may include changes in mood (such as anxiety or depression) and sleep disturbances (such as insomnia). These effects are documented in official safety information, with their frequency classified as unknown or very rare.


Q: Are there any known long-term effects of using Clenil 50 mcg?

Official documentation notes that systemic effects, such as a decrease in bone mineral density and adrenal suppression, are more likely to occur with high doses used for prolonged periods. Furthermore, regulatory documents advise that the growth rate of children using the medication for extended periods should be monitored closely.


Q: Can Clenil 50 mcg affect my eyes or vision?

The official safety profile documents potential ocular (eye-related) adverse effects. Eye disorders, including cataracts and glaucoma, are listed as very rare potential adverse effects. Blurred vision is also reported as an effect with an unknown frequency.


Q: What should I look out for that indicates Clenil 50 mcg is not working?

Official product information describes that signs of inadequate asthma control include a decrease in peak flow measurements or a worsening of asthma symptoms in general. Another key indicator is a need for increased use of your fast-acting rescue inhaler.


Q: What are the known benefits of using a spacer device with Clenil 50 mcg?

Official labeling recommends or mandates the use of a spacer device, particularly in children. The official documentation states the benefits include improved drug deposition into the airways and enhanced overall effectiveness of the treatment.


Q: Does Clenil 50 mcg show up on drug tests?

In contexts such as athletic competitions, official anti-doping regulations (e.g., from the World Anti-Doping Agency) classify inhaled corticosteroids, including beclomethasone, as permitted at all times for therapeutic use. This means their presence is not prohibited in standard sports testing when used as prescribed.


Q: Is it normal to cough immediately after using the Clenil 50 mcg inhaler?

Official labeling lists throat irritation as a common side effect of the medicine. However, regulatory warnings also note the low-frequency potential for paradoxical bronchospasm—an immediate and severe increase in wheezing or difficulty breathing—which is a serious event that requires urgent treatment.


Q: Is there a generic version of Clenil 50 mcg available?

The availability of generic medicines is managed by official drug approval databases in each region. These databases indicate that a therapeutically equivalent generic version of the beclomethasone dipropionate metered-dose inhaler may not be currently available in all markets.


Q: Can I travel with my Clenil 50 mcg inhaler on an airplane?

Government security regulations (e.g., TSA in the US) generally allow travelers to carry medically necessary aerosols such as inhalers in carry-on baggage. These items are typically required to be declared to security personnel for screening.


Q: Do studies suggest Clenil 50 mcg is suitable for people with diabetes?

Official product information notes that patients with diabetes or high blood sugar are advised to use caution, as the corticosteroid class can affect metabolic processes. This warning is due to the potential for systemic effects from the drug.

Advertisements

How should Clenil 50 mcg be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing and disposing of the Clenil 50 mcg pressurized inhalation solution to maintain product integrity and safety.

Storage Conditions

Requirement Constraint
Temperature Limit Store at a temperature not exceeding 30 C.
Handling & Protection Must be protected from direct sunlight and frost.
Pressurized Canister Contents are under pressure; do not puncture or store near heat or open flame.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Expired or unused Clenil 50 mcg must not be disposed of via household waste or wastewater. Disposal must follow pharmaceutical waste guidelines, requiring the medicine to be returned to a pharmacist. These measures help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clenil 50 mcg found in:

A-Z Index: